Published May 2018
| Version v1
Journal article
Dose escalation for prostate stereotactic ablative radiotherapy (SABR): Late outcomes from two prospective clinical trials
Creators
- 1. Department of Radiation Oncology, University of Toronto, Toronto, ON (Canada)
- 2. Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON (Canada)
- 3. Tom Baker Cancer Institute, Calgary, AB (Canada)
- 4. Department of Human Oncology, University of Wisconsin, Madison (United States)
- 5. Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON (Canada)
- 6. Institute of Health Policy, Measurement & Evaluation, University of Toronto, Toronto, ON (Canada)
Description
Purpose: Optimal prostate SABR dose-fractionation is unknown. This study compares long-term outcomes from two prospective trials.
Availability note (English)
Available from http://dx.doi.org/10.1016/j.radonc.2018.03.005Additional details
Identifiers
- DOI
- 10.1016/j.radonc.2018.03.005;
- PII
- S0167814018301373;
Publishing Information
- Journal Title
- Radiotherapy and Oncology
- Journal Volume
- 127
- Journal Issue
- 2
- Journal Page Range
- p. 213-218
- ISSN
- 0167-8140
- CODEN
- RAONDT
INIS
- Country of Publication
- Ireland
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 50081057
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- CLINICAL TRIALS; FRACTIONATED IRRADIATION; NEOPLASMS; PROSTATE; RADIATION DOSES; RADIOTHERAPY
- Descriptors DEC
- BODY; DISEASES; DOSES; GLANDS; IRRADIATION; MALE GENITALS; MEDICINE; NUCLEAR MEDICINE; ORGANS; RADIOLOGY; TESTING; THERAPY
Optional Information
- Copyright
- Copyright (c) 2017 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.